



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2023 #14

April 14, 2023

## INSIDE:

Donor Gender Not Associated with Transfusion Mortality ....	2
CMS Releases Proposed Rule for Hospital IPPS..	2
ABC Names Director of Scientific and Technical Operations.....	3
WORD IN WASHINGTON .....	3
RESEARCH IN BRIEF ....	4
ABC Supports Blood Donation Tax Credit Bill during Testimony before the Tax Policy Committee of the Michigan House.....	5
Participate in ABC's Blood Advocacy Week.....	5
Save the Date: ABC Summer Summit & MD Workshop .....	6
Participate in Day on Capitol Hill .....	6
MEMBER NEWS.....	6
GLOBAL NEWS .....	7
COMPANY NEWS .....	7
CALENDAR.....	8
POSITIONS.....	9

## CMS Seeks Feedback on Palliative Blood Transfusion

The Centers for Medicare and Medicaid Services (CMS) is soliciting feedback regarding palliative blood transfusions in the Medicare Program; Fiscal Year 2024 Hospice Wage Index and Payment Rate Update, Hospice Conditions of Participation Updates, Hospice Quality Reporting Program Requirements, and Hospice Certifying Physician Provider Enrollment Requirements [proposed rule](#). Specifically, the agency is seeking public feedback and comments on questions that include:

- “are there any enrollment policies for hospices that may be perceived as restrictive to those beneficiaries that may require higher cost end of life palliative care, such as blood transfusions, chemotherapy, radiation, or dialysis?”
- What continued education efforts do hospices take to understand the distinction between curative treatment and complex palliative treatment for services such as chemotherapy, radiation, dialysis, and blood transfusions as it relates to beneficiary eligibility under the hospice benefit? How is that information shared with patients at the time of election and throughout hospice service?”

[Comments](#) are due May 30<sup>th</sup>. America’s Blood Centers (ABC) will be submitting comments to the agency and encourages member blood centers to also provide comments on the proposed rule to CMS as well. This topic is a priority of the [2023 Advocacy Agenda](#) as ABC aims to ensure blood transfusions are available to patients when and where they need blood. Due to bundled payments in the Medicare Hospice program, blood transfusions are not broadly available to patients in the hospice setting. As a result, patients in need of palliative transfusions often do not enroll in the hospice benefit resulting in greater Medicare expenditures with lower quality end of life care. By fairly reimbursing providers for the cost of providing this quality of life preserving care, patients are assured the care they need when and where required.

Additionally, ABC will feature this [topic](#) as a part of [Blood Advocacy Week](#) discussions on Thursday, April 27<sup>th</sup>. [Register](#) today to join the conversation. Please contact ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#) with questions.

(Source: CMS [Proposed Rule](#), 4/4/23) 💧





## Donor Gender Not Associated with Transfusion Mortality

Researchers in Canada have [published](#) findings in the *New England Journal of Medicine* from a clinical trial that examined the “effect of Donor Sex on Recipient Mortality in Transfusion.” According to a news release [announcing](#) the results, the double-blind, randomized trial included 8,719 enrolled patients. It excluded “those who were massively bleeding and needed blood right away, and those with a complex antibody profile which made blood unit matching difficult. Study participants were randomly assigned to receive either male or female donor blood at all visits to The Ottawa Hospital during the study period. 80 percent of patients received their first transfusion while they were an inpatient, and 42 percent of those received it during surgery.” The researchers explained in the publication that the “trial did not show an overall survival benefit with a strategy of red-cell transfusion from a male blood donor as compared with a strategy of red-cell transfusion from a female donor.” Co-lead author Dean Fergusson, PhD, a senior scientist at The Ottawa Hospital, director of the hospital’s Clinical Epidemiology Program, and professor at the University of Ottawa, added in the news release “some observational studies had suggested female donor blood might be linked with a higher risk of death among recipients compared to male donor blood, but our clinical trial found that isn’t the case.”

**Citation:** Chassé, M., Fergusson, D., Tinmouth, A., *et al.* “[Effect of donor sex on recipient mortality in transfusion.](#)” *New England Journal of Medicine*. 2023.

(Source: American Association for the Advancement of Science [News Release](#), 4/12/23) 💧

## CMS Releases Proposed Rule for Hospital IPPS

The Centers for Medicare and Medicaid Services (CMS) has issued the [proposed rule](#) for “the Hospital Inpatient Prospective Payment Systems (IPPS) for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year (FY) 2024 Rates.” The proposed rule includes a 2.8 percent rate increase over FY23. CMS pays hospitals for inpatient stays using the IPPS, which sets base payment rates for a patient’s stay based on the patient’s diagnosis and severity of illness. A hospital is not paid for the cost of providing care to a specific patient, but instead is given a single payment based on the patient’s diagnostic related group (DRG) with certain add-ons and adjustments. Additionally, hospitals are not reimbursed separately for blood products. Each year, CMS must reassess the payment rate to reflect hospital reporting of the price of goods and services used to treat all Medicare patients (known as the market basket). The proposed rule is scheduled to be published in the *Federal Register* on May 1<sup>st</sup>. CMS is accepting comments on the proposed rule until June 9<sup>th</sup>. A summary of the rule changes for FY24 is available on the CMS [website](#). America’s Blood Centers (ABC) encourages member blood centers to provide any feedback, comments, or questions to ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#).

(Source: CMS [Proposed Rule](#), 4/10/23) 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry  
Chief Medical Officer: Jed Gorlin  
Editor: Mack Benton  
Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$390**

Send subscription queries to  
[memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
America’s Blood Centers  
1717 K St. NW, Suite 900, Washington, DC 20006  
Phone: (202) 393-5725  
Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



## ABC Names Director of Scientific and Technical Operations

America's Blood Centers (ABC) announced this week that Betzy Gonzalez, MS, BB(ASCP) will be the new director of Scientific and Technical Operations beginning April 24<sup>th</sup>. She succeeds Toni Mattoch who retired from ABC on March 31<sup>st</sup> after 15 years.

Ms. Gonzalez is an experienced blood banking professional with knowledge and expertise that encompasses the technical, operational, quality, and regulatory aspects of the industry. She began her career in a hospital-based blood bank as a licensed medical laboratory professional where she developed a strong foundation in patient/donor/product testing, blood component manufacturing, and quality control. Ms. Gonzalez continued to grow her technical expertise and leadership abilities in her role as a transfusion services laboratory manager. In addition to leading the operations of the transfusion services, she served as a CAP inspector, a member of both the Blood Utilization and Safety Committees and was a mentor/educator to the pathology residents as well as the medical laboratory students. Ms. Gonzalez then made the transition from hospital laboratory operations to the quality and regulatory space of blood banking where she has spent the last nine years of her career providing regulatory and technical guidance to achieve operational excellence. She has served on ABC's Quality Assurance (QA) Blood Regulatory Review group and the Quality Assurance Committee. Ms. Gonzalez holds a Master of Science in Clinical Laboratory Sciences – Immunology and a Certificate in Immunohematology from Florida International University. She also holds an ASCP certification in Blood Banking and is licensed as a Florida Clinical Laboratory Supervisor. She can be reached at [bgonzalez@americasblood.org](mailto:bgonzalez@americasblood.org).

(Source: [MCN 23-036](#), 4/13/23) ◆

## WORD IN WASHINGTON

**The Centers for Disease Control and Prevention [published](#) data showing an increase in sexually transmitted infections (STIs) from 2020-2021.** According to the surveillance data from the agency, more than 2.5 million cases of STIs were reported with a 32 percent surge in syphilis rates from 133,954 to 176,713.

(Source: CDC [News Release](#), 4/11/23)

**President Biden signed a [bill](#) this week that terminates the COVID-19 national emergency.** This bill is separate from the COVID-19 public health emergency (PHE) that is scheduled to end on May 11<sup>th</sup>. The U.S. Department of Health and Human Services (HHS) announced clarification to its COVID-19 Emergency Use Authorization (EUA) declarations last month in a notice published in the *Federal Register*. The agency stated that EUAs for biological and medical products issued during the COVID-19 public health emergency (PHE) “will remain in effect” after the conclusion of the COVID-19 PHE on May 11<sup>th</sup>. EUAs are independent of the PHE declaration by the administration.

(Source: The White House, [Bill Signed: H.J.Res. 7](#), 4/10/23)

**The National Biodefense Science Board (NBSB) will hold a virtual public meeting on May 4<sup>th</sup> according to an [announcement](#) published in the *Federal Register*.** “The NBSB, managed and operated by the Administration for Strategic Preparedness and Response (ASPR), provides expert advice and guidance to the Secretary of HHS regarding current and future chemical, biological, radiological, and nuclear threats, and other disaster preparedness and response matters.”

(Source: *Federal Register* [Notice](#), 3/15/23) ◆



## RESEARCH IN BRIEF

**Platelet and Cryoprecipitate Transfusions from Females Improve Coagulopathy *In Vitro*.** A study in the *Journal of Trauma and Acute Care Surgery* evaluated “the hemostatic differences in sex concordant and sex discordant cryoprecipitate and platelet transfusions.” The authors explained that “whole blood was collected from healthy volunteers 18 years or older, and younger than 55 years to exclude females in menopause.” They noted that “samples of 99 healthy volunteers were included, 47 percent were female with a median age of 30 years.” The study found that “there was increased fibrinogen activity and fibrin contribution to clot strength in female plasma...In contrast, there was no sex difference in total fibrinogen.” The researchers stated that “transfusion experiments included 10 female and 10 male platelet donors, eight female and eight male cryoprecipitate donors, and 10 male and 10 female recipients.” They explained that “in male recipients, female-donor platelets induced a shorter time to clot formation (R time) than male-donor platelets...In female recipients, female and male platelets induced similar decreases in R time ( $p > 0.05$ )...In addition, there were no sex differences in [clot strength] MA or [rate of clot propagation] angle induced by platelets in either sex recipient.” The authors noted that “female-donor cryoprecipitate increased angle and shortened R time more than male-donor cryoprecipitate in both male and female recipients...There were increased total factor XIII (FXIII) levels in female-donor cryoprecipitate, with a 1.46-fold increase in FXIII $\alpha$ , the active subunit of FXIII...There was increased factor V in female-donor cryoprecipitate, although this failed to reach statistical significance ( $p = 0.054$ ).” They explained that “there was a significant decrease in PT and a trend toward decreased PTT ( $p = 0.06$ ) in female-donor cryoprecipitate indicating more rapid activation of both the intrinsic and extrinsic clotting pathways...[The] proteomic [data] revealed there were 28 proteins with significant differences between male and female donors.” The authors concluded that “blood products from females induce superior improvements in coagulopathy compared with male-donor blood products *in vitro*...Increased factor V and FXIII activity as well as increased fibrinogen activity in female donors appears to drive this sex disparity...The differing hemostatic profile of female- and male-donor blood products suggests a role for sex-specific transfusion guidelines in hemostatic resuscitation.”

**Citation:** DeBot, M., Erickson, C., Kelher, M., *et al.* [Platelet and cryoprecipitate transfusions from female donors improve coagulopathy \*in vitro\*](#). *J Trauma Acute Care Surg*. 2023.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧





**America's Blood Centers**  
It's About *Life*.

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.*

### **ABC Supports Blood Donation Tax Credit Bill during Testimony before the Tax Policy Committee of the Michigan House**

America's Blood Centers (ABC) Senior Director of Federal Government Affairs Diane Calmus, JD [testified](#) before the Michigan House Tax Policy Committee on April 12<sup>th</sup> in support of [House Bill \(HB\) No. 4068](#). The legislation would allow “[f]or tax years that begin on and after January 1, 2023, a taxpayer may claim a credit against the tax imposed by this part equal to \$25 for each verified blood donation made during the tax year” to a non-profit blood bank. During her testimony, Ms. Calmus stated “[w]e have seen tax credits focused on incentivizing businesses’ drives in other states help blood centers schedule blood drives and bring in necessary blood donations. However, HB 4068 is different in an important way, it is in line with the changing way blood collection is occurring, at the level of the individual instead of the business. You have the opportunity to incentivize Michiganders to take part in caring for their community by donating blood.” ABC member Versiti Blood Center of Michigan also testified in the support of the bill.



(Sources: Michigan [House Bill No. 4068](#), 2/2/23; [ABC Testimony](#), 4/12/23)

### **Participate in ABC's Blood Advocacy Week**

ABC is hosting the inaugural [Blood Advocacy Week](#) April 24<sup>th</sup>-28<sup>th</sup>. This initiative reinforces ABC's commitment to advocacy and advancing policies that assist community blood centers. These virtual events aim to bring together members of the blood community, legislators, agency decision makers, advocates, providers, patients, and more to learn about and advance ABC's advocacy efforts on behalf of member blood centers. It includes the following:

- Monday, April 24<sup>th</sup> will be dedicated to discussing the current [status](#) of the nation's blood supply and trends impacting the collection and utilization of blood. Registration for the day's virtual event is [now open](#).
- Tuesday, April 25<sup>th</sup> will be dedicated to promoting the awareness of FDA donor [eligibility](#) changes impacting veterans and gay and bisexual men. Registration for the day's virtual event is [now open](#).
- Wednesday, April 26<sup>th</sup> will be ABC's virtual “Day on Capitol Hill.” [Registration](#) is now open.
- Thursday, April 27<sup>th</sup> will be dedicated to examining changes that will expand early and increased access to blood, including in [pre-hospital](#) and [hospice](#) settings. Registration for the day's virtual event is [now open](#).
- Friday, April 28<sup>th</sup> will be dedicated to highlighting why increased [diversity](#) – racial, ethnic, and age – is important to patient care. Registration for the day's virtual event is [now open](#).

(continued on page 6)



## INSIDE ABC (continued from page 5)

ABC thanks Fresenius Kabi for being a Blood Advocacy Week sponsor. If you or your organization is interested in becoming an official [advocacy partner](#) or [sponsor](#), please contact [Jeff Gohringer](#), director of Strategic Communications and National Partnerships at ABC.

### Save the Date: ABC Summer Summit & MD Workshop

Mark your calendars for America's Blood Centers (ABC) [Summer Summit and Medical Directors Workshop](#) in St. Louis, Mo. The meeting will take place August 1<sup>st</sup>-3<sup>rd</sup>. Hotel [reservations](#) can be made now through the ABC block at Live! by Loews (St. Louis). Attendees will hear updates on blood center operational, scientific, and medical issues, case studies, engaging discussions, and have networking opportunities to connect with peers and colleagues. Additional details, including registration information and a preliminary agenda, are coming soon.

### Participate in Day on Capitol Hill

ABC encourages all member blood centers to register for the [2023 Day on Capitol Hill \(Virtual\)](#) on April 26<sup>th</sup>. This virtual day provides an opportunity for member blood centers to connect with members of Congress and their staffs to discuss the ongoing work at the blood center and the work done collectively by ABC and community blood centers to advance the [ABC Advocacy Agenda](#). This event is a chance for individuals to let their voice be heard. ABC will arrange virtual meetings for member blood centers with their members of Congress and provide additional resources to help inform them and their staff about the latest policies impacting the blood community. Take advantage of this opportunity to easily meet with your local Congressional leaders and build relationships.

Each person from the blood center who would like to participate in the Day on Capitol Hill must register individually. ABC will arrange for group meetings but will need information for each person in attendance. Please direct any questions to ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#).

(Source: [MCN 23-020](#), 2/24/23) ♦

## MEMBER NEWS



**Our Blood Institute** recently [launched](#) the “Faith in Blood” initiative designed to “highlight the lifesaving act of donating blood as a spiritual practice.” According to a news release announcing the launch, “the initiative demonstrates how blood donation puts faith into action with dynamic resources for diverse denominations.” Our Blood Institute President and Chief Executive Officer John Armitage, MD stated in the news release, “Faith in Blood was created to inspire people of faith across the globe to participate in and advocate for blood donation as part of their religious devotion. Whether believers worship at churches, mosques, synagogues, or other temples, we honor their decision to give blood as a service to their community and as a testament to their faith. The commonality of all participants is a commitment to religious identity.” The initiative’s [website](#) contains “content for the three major Abrahamic religions, Christianity, Islam and Judaism, and includes separate resources for each major religion...[The resources are designed for] blood drive hosts, religious leaders, potential donors and even recipients of blood donation, with faith-based answers to frequently asked questions, printable materials, online games and more.”

(Source: Our Blood Institute [News Release](#), 4/11/23) ♦



## GLOBAL NEWS

The World Health Organization (WHO) has [published](#) the report from the most recent meeting of the Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). The March 16<sup>th</sup>-17<sup>th</sup> meeting took place to “assess the performance of updated COVID-19 vaccines that incorporated descendent lineages of [the] Omicron [variant] includ[ing] published observational epidemiological studies, laboratory-based data, and laboratory-based studies and observational data on immune memory responses to evaluate the impact of repeated antigen exposure on vaccine-induced immunity and protection.” After reviewing the available data, the TAG-CO-VAC concluded:

- booster doses of index virus-based vaccines continue to confer high levels of protection against severe disease and death caused by all SARS-CoV-2 variants, including contemporary Omicron descendent lineages;
- Protection from severe disease and symptomatic infection induced by index virus-based vaccines and BA.1- or BA.4/5-containing bivalent mRNA vaccines declines over time. However, protection from severe disease is maintained longer than protection from symptomatic infection;
- as compared to index virus-based vaccines, booster doses of BA.1- or BA.4/5-containing bivalent mRNA vaccines may modestly increase vaccine effectiveness against symptomatic disease, while the small number of studies assessing severe outcomes show similar estimates of vaccine effectiveness; [and]
- both BA.1- and BA.4/5-containing bivalent mRNA vaccines enhance the magnitude and elicit greater breadth of cross-reactive immune responses to SARS-CoV-2 variants when used as a booster dose, as compared to the index virus-based vaccines.”

(Source: WHO [Statement](#), 4/14/23)

Ghana has approved a malaria vaccine [developed](#) at Oxford University for use “in children aged five to 36 months.” According to a news release, “[t]he [vaccine] has demonstrated high levels of efficacy and safety in Phase II trials, including amongst children who received a booster dose of [the vaccine] at one year following a primary three-dose regime...The vaccine contains Novavax’s Matrix-M, a saponin-based adjuvant that enhances the immune system response, making it more potent and more durable. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes.”

(Source: Oxford University [News Release](#), 4/13/23) 💧

## COMPANY NEWS

Hemanext and the Sickle Cell Disease Association of America (SCDAA) recently [partnered](#) with America’s Blood Centers member OneBlood to host the first of several planned blood drives to raise and increase awareness of “the importance of diversity in the blood donor pool.” The inaugural blood drive took place on April 1<sup>st</sup>. “We are thrilled to collaborate [with] the local SCDAA chapter, OneBlood and Hemanext,” said SCDAA President and Chief Executive Officer (CEO) Regina Hartfield in a news release. “At SCDAA, we understand the vital importance of diversifying the blood donor pool.” Hemanext CEO Martin Cannon added in the news release, “Hemanext is dedicated to improving transfusion therapy and we are always seeking ways to achieve our mission of safer transfusions and healthier patients. Since transfusions rely upon a robust blood supply through donors, it aligns with our goals to help support solutions to address unmet needs in this area.”

(Source: Hemanext [News Release](#), 3/31/23)

(continued on page 8)


COMPANY NEWS (continued from page 7)

A recent [announcement](#) from **bluebird bio** stated the company has responded to a request for additional information from the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy (lovotibeglogene autotemcel) to treat sickle cell disease. According to a company news release, the anticipated biologics license application (BLA) submission is “progressing” and “[i]n early March, the [bluebird bio] responded to feedback from the FDA on vector and drug product analytical comparability evaluations completed in December 2022; bluebird expects a response from the FDA within a matter of weeks and will move quickly to expedite its BLA submission, pending alignment with FDA on product comparability. bluebird bio plans to request priority review for patients 12 and older with a history of vaso-occlusive events. If approved, bluebird continues to anticipate a commercial launch in early 2024.”


(Source: bluebird bio [News Release](#), 3/29/23) ♦

**Upcoming ABC Webinars – Don’t Miss Out!**

- **ABC Blood Advocacy Week 2023** – April 24-28. [Registration](#) for events each day of the week as well as [ABC’s Day on Capitol Hill](#) (members-only) is open and the initial list of partners is now [available](#). More information available [here](#).
- **Héma-Québec’s Perspective – Implementation Experience with Individual Donor Assessment** – May 17 from 3-4 PM EDT. More information coming soon.



America's Blood Centers  
It's About *Life*.



ADRP  
An International Division of ABC

**CALENDAR**

*Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org). (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

**2023**

April 20. **End of Selection Criteria Based on Sexual Orientation – International Symposium on Alternatives to Donation Deferral (Virtual)**. [Registration](#) is open. More information available [here](#).

April 24-28. **ABC Blood Advocacy Week (Virtual)**. More information available [here](#).

April 25. **U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) Town Hall: Gene Therapy Chemistry, Manufacturing, and Controls – April 2023 (Virtual)**. [Registration](#) is open. More information available [here](#).

April 26. **ABC Day on Capitol Hill (Virtual)**. [Registration](#) is open. More information available [here](#).

April 26. **FDA Blood Products Advisory Committee (BPAC) Meeting (Virtual)**. More information available [here](#).

(continued on page 9)



## CALENDAR (continued from page 8)

April 27. **FDA's CBER Office of Tissues and Advanced Therapies (OTAT) Public Listening Meeting: Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products (Virtual).** [Registration](#) is open. More information available [here](#).

May 4. **The National Biodefense Science Board, managed and operated by the Administration for Strategic Preparedness and Response, Public Meeting (Virtual).** [Registration](#) is open. More information available [here](#).

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** [Registration](#) is open. Additional information is available [here](#).

May 10-11. **29<sup>th</sup> IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Bologna, Italy.** More information available [here](#).

May 17. **Héma-Québec's Perspective – Implementation Experience with Individual Donor Assessment.** More information coming soon.

Aug. 1-3. **ABC Medical Directors Workshop and Summer Summit, St. Louis, Mo.** More information available [here](#).

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Sept. 20-21. **2023 ADRP Master Class (Virtual).** More information coming soon.

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#)

Oct. 18-20. **American Society for Clinical Pathology (ASCP), Long Beach, Calif.** More information available [here](#). ♦

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Instructor – Collections Training (Carter BloodCare).** Principal Accountability: The Instructor position is responsible for the training and continuing education of the Collection Services staff in all procedures involved in the blood collection process. This includes but is not limited to medical history, donor lookup, phlebotomy, quality control, and CPR. This position is responsible for ensuring that trainees receive adequate clinical experience, safely performing all required skills and successfully completing competency testing. This position plans for and guides the learning process to help students achieve required objectives. The Instructor should be able to communicate information in a clear manner both verbally and in writing, should be able to use a computer to make schedules, input data and run reports. The Instructor must have adequate transportation to travel throughout our coverage area when needed. This position is required to maintain regular full-time attendance during office hours and may be required to work overtime. Education: High school diploma or equivalent.

Some college a plus. Experience: Six months supervisory experience required; Minimum of one year of blood banking preferred; Six months apheresis experience preferred; and Some experience teaching adults preferred. Equal Opportunity Employer: Disability/Veteran. Apply at [www.carterbloodcare.org](http://www.carterbloodcare.org), click Careers & search for job # 38784.

**Community and Diversity Outreach Specialist – Community Relations (Carter BloodCare).** Principal Accountability: The primary responsibility of the Community and Diversity Outreach Specialist is to develop a program and outreach initiatives focused on Carter BloodCare's Hispanic and/or Black blood donor heritage and historically underrepresented communities. This individual will perform a wide range of duties to coordinate, such as helping create the strategic plan and

(continued on page 10)

## POSITIONS (continued from page 9)

organizing day-to-day operations. The incumbent demonstrates an understanding of and commitment to quality healthcare, donor diversity, and excellent customer service, acting as a key public facing liaison working closely with donor recruitment, medical services, marketing, and public relations. Individual must be

regularly available to work at least 8 hours per day, 40 hours per week. Regular full-time attendance is required during office hours. Education: bachelor's degree in marketing, Business, Communications, Minority Studies or other related field from an accredited four-year college or university, preferred. Experience of two years with non-profit fundraising, public administration, or outreach activities. Experience: Minimum two years' experience; Blood Banking experience preferred; and Bilingual in Spanish language is required for Hispanic Outreach. Equal Opportunity Employer: Disability/Veteran. Apply at [www.carterbloodcare.org](http://www.carterbloodcare.org), click Careers & search for job # 39087.

**Director of Donor Resources.** The Northern California Community Blood Bank (NCCBB) seeks an exuberant and outgoing team player with extraordinary people skills to join us as Director of Donor Resources. Located in the heart of the magnificent coastal redwoods of Northern California, NCCBB offers the opportunity to be part of an organization with a vibrant community relationship and a mission that can be personally gratifying and meaningful. The Director of Donor Resources is responsible for the development and direction of programs related to recruitment and retention of blood donors in Humboldt and Del Norte Counties. The Director oversees all recruitment efforts, ensuring that they reach collection targets and are in accordance with regulatory standards. Recruitment efforts include mobile and in-house blood drives, community outreach and education, marketing, and publicity. The Director oversees programs for telephone, text, and email donor recruitment. For details and to apply, visit [www.nccbb.net/employment.html](http://www.nccbb.net/employment.html).

**Enterprise Medical Director.** This position is part of an enterprise-wide Chief Medical Office. This role is responsible for providing medical directorship, administrative, technical, and clinical operations of the assigned hospitals, systems, program, and services as well as support medical directorship of New York Blood Center (NYBC) or the greater NYBC enterprise. This position supports management in making information medical decisions, develops and reviews medical oversight and responsibility for the technical and medical policies, processes, and procedures of specific operations. New York Blood Center Enterprises (NYBCe) is one of the largest community-based, non-profit blood collection and distribution organizations in the United States. We proudly serve as a vital community lifeline dedicated to serving patients and advancing global public health. Our four-part mission is to provide high quality blood products, therapeutic apheresis, cord, and stem cell services, conduct innovative research, develop new products and technologies, and train the next generation of industry leaders. We serve more than 600 hospitals through our six east coast and mid-west divisions and work with dozens of research organizations, academic institutions, and biopharmaceutical companies through our five research enterprises. Click here to view the full job description and apply: [Enterprise Medical Director in New York, New York.](#) 💧